Bellerophon Therapeutics, Inc.
BLPH
BLPH was delisted on the 13th of October, 2023.
19 hedge funds and large institutions have $1.4M invested in Bellerophon Therapeutics, Inc. in 2022 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 6 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
14% less funds holding
Funds holding: 22 → 19 (-3)
48% less capital invested
Capital invested by funds: $2.68M → $1.4M (-$1.28M)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$32.2K |
| 2 |
SC
Sepio Capital
Salt Lake City,
Utah
|
+$31.8K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$19.2K |
| 4 |
DWM
Destination Wealth Management
Walnut Creek,
California
|
+$13.4K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$12.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$88K |
| 2 |
BlackRock
New York
|
-$26.8K |
| 3 |
Millennium Management
New York
|
-$26K |
| 4 |
TI
Telemetry Investments
New York
|
-$19.5K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$6K |
BLPH Hedge Fund Activity: Q2 2022 in Review
19 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q2 2022, worth a combined $1.4M — down 48% from $2.68M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of BLPH and 3 opened new positions — a net loss of 3 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $32.2K. The largest seller was Jane Street, exiting entirely with an estimated $88K sold.
- 19 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q2 2022, down from 22 in Q1 2022.
- Funds reported $1.4M of Bellerophon Therapeutics, Inc. stock for Q2 2022, down 48% quarter-over-quarter.
- 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q2 2022 and 6 closed out, a net change of -3 holders.
- The largest Bellerophon Therapeutics, Inc. buyer in Q2 2022 was Renaissance Technologies, an estimated $32.2K added.
- The largest Bellerophon Therapeutics, Inc. seller in Q2 2022 was Jane Street, an estimated $88K sold.
Based on aggregated 13F filings for Q2 2022.